at Zacks.com (Wed, 12:00PM)
The effectiveness of Novartis' (NVS) immune-system drug Certican was confirmed in the largest trial to date of liver-transplant patients, with the treatment also able to improve renal function in the two-year Phase III study. Certican is approved in the EU for liver transplant patients, with an FDA approval decision expected at the end of the year. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Tue, 3:46AM)
at Investor's Business Daily (Mon, 8:02AM)
at Zacks.com (Fri, 5:50PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs